Editas CSO sells 709 shares in tax-plan trade

Editas Medicine’s chief scientific officer reported an automated, tax-related sale of 709 shares under a pre-arranged plan, leaving her with 61,660 shares.

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) reported that EVP and Chief Scientific Officer Linda Burkly sold 709 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share, in an open-market transaction.

According to the company’s disclosures, the sale was effected under a durable automatic sales instruction plan adopted on July 3, 2023 and represents shares sold by Editas Medicine to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 2, 2026, rather than a discretionary trade by Burkly. After this transaction, she held 61,660 shares of Editas Medicine common stock directly. The transaction price reflects a weighted average for multiple trades executed between $3.0050 and $3.0372 per share.

Insider Trade Summary 10b5-1

Net Seller: 709 shares

Net Sell 1 txn

Insider Burkly Linda

Role EVP, CHIEF SCIENTIFIC OFFICER

Sold 709 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	709	$3.0372	$2K

Holdings After Transaction: Common Stock — 61,660 shares (Direct)

Footnotes (2)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
2. F2. This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 709 shares Weighted average sale price: $3.0372 per share Post-transaction holdings: 61,660 shares +3 more

6 metrics

Shares sold 709 shares Common stock sale reported for September 3, 2026

Weighted average sale price $3.0372 per share Common stock sold in multiple trades on September 3, 2026

Post-transaction holdings 61,660 shares Common stock held directly by Linda Burkly after the sale

Trade price range $3.0050 to $3.0372 per share Range of prices for the multiple trades comprising the sale

Plan adoption date July 3, 2023 Durable automatic sales instruction plan used for the sale

RSU vesting date September 2, 2026 Vesting event that created the tax withholding obligation

Key Terms

durable automatic sales instruction plan, restricted stock units, weighted average purchase price, tax withholding obligations

4 terms

durable automatic sales instruction plan regulatory

"Sale was effected pursuant to a durable automatic sales instruction plan adopted"

restricted stock units financial

"as a result of vesting in restricted stock units on September 2, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average purchase price financial

"The price reported above reflects the weighted average purchase price"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

tax withholding obligations financial

"necessary to meet tax withholding obligations as a result of vesting"

FAQ

What insider transaction did EDIT report for EVP and Chief Scientific Officer Linda Burkly?

Editas Medicine reported that Linda Burkly sold 709 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share, executed as an open-market transaction.

Was the September 3, 2026 EDIT insider sale by Linda Burkly discretionary?

No. The filing states the sale was made under a durable automatic sales instruction plan adopted on July 3, 2023 and represented shares sold to cover tax withholding obligations from RSU vesting, not a discretionary trade.

How many EDIT shares does Linda Burkly hold after the reported sale?

After selling 709 shares, Linda Burkly directly holds 61,660 shares of Editas Medicine common stock, as reported in the Form 4 following the September 3, 2026 transaction.

What price range applied to the EDIT shares sold by Linda Burkly?

The transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372 per share. The filing reports a $3.0372 weighted average price for the sale of 709 shares.

Why were EDIT shares sold in connection with RSU vesting for Linda Burkly?

The company reports that the 709 shares were sold by Editas Medicine to meet tax withholding obligations triggered by the vesting of restricted stock units on September 2, 2026, under a pre-established sales instruction plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:28 PM Accepted by SEC EDGAR 09/04/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkly Linda

(Last) (First) (Middle)

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S(1)		709	D	$3.0372(2)	61,660	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Linda C. Burkly	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)